Home › Research › Prevention and risk
Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study
Zimmerman SC, Choi M, Jiang C, Ferguson EL, Hoffmann TJ, Swinnerton K, Oni-Orisan A, Gilsanz P, Meyers TJ, Choudhary V, et al.. Neurology, 2025-06-27
Topic: Risk, prevention and care in population studies
Plain-language summary
Results Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). In the first year after initiating statins, AD/ADRD diagnoses were elevated by 46% (hazard ratio [HR] = 1.46, 95% CI 1.42-1.53) compared with noninitiators. Classification of evidence This emulated trial provides Class II evidence that statin initiation is not associated with AD/ADRD or AD incidence after the first year of follow-up.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study of 322,358 participants. This emulated trial found that statin initiation was not associated with Alzheimer's disease or related dementias after the first year of follow-up. Reported effect size: HR 1.00 (95% CI 0.99-1.01) for dementia after the first year of statin initiation.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zimmerman, S. C., Choi, M., Jiang, C., Ferguson, E. L., Hoffmann, T. J., Swinnerton, K., et al. (2025). Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study. Neurology. https://doi.org/10.1212/WNL.0000000000213855
Vancouver
Zimmerman SC, Choi M, Jiang C, Ferguson EL, Hoffmann TJ, Swinnerton K, et al. Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study. Neurology. 2025. doi:10.1212/WNL.0000000000213855. PMID: 40577672.
BibTeX
@article{zimmerman2025-40577672,
author = {Zimmerman, S. C. and Choi, M. and Jiang, C. and Ferguson, E. L. and Hoffmann, T. J. and Swinnerton, K. and Oni-Orisan, A. and Gilsanz, P. and Meyers, T. J. and Choudhary, V. and others},
title = {{Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020: A Target Trial Emulation Study}},
journal = {Neurology},
year = {2025},
doi = {10.1212/WNL.0000000000213855},
pmid = {40577672},
url = {https://doi.org/10.1212/WNL.0000000000213855}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female).
- In the first year after initiating statins, AD/ADRD diagnoses were elevated by 46% (hazard ratio [HR] = 1.46, 95% CI 1.42-1.53) compared with noninitiators.
- Classification of evidence This emulated trial provides Class II evidence that statin initiation is not associated with AD/ADRD or AD incidence after the first year of follow-up.
Why it matters
This emulated trial found that statin initiation was not associated with Alzheimer's disease or related dementias after the first year of follow-up. Diagnoses were elevated in the first year after starting statins, which the study design suggests may reflect detection rather than a true effect.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort
- Participants322,358
- Effect sizeHR 1.00 (95% CI 0.99-1.01) for dementia after the first year of statin initiation
- Evidence strengthHigh
Limitations
Intent-to-treat analysis does not measure long-term adherence or cumulative dose; single integrated health system; observational despite target-trial design.
How this study scored 66/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 65 of the 98 points we could judge it on, which is 66 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 322,358 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author M. Maria Glymour: h-index 83 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40577672) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 65 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 65 of the 98 points we could judge it on is 66 out of 100. |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/WNL.0000000000213855
- PubMed: 40577672
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Prevention and risk from nearby years
Also tagged “statin-lipid-lowering-and-dementia”
5 studies in the library carry the topic tag “statin-lipid-lowering-and-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.